Unknown primary tumors: is there a future therapeutic role for immune checkpoint inhibitors?

Hampig Raphael Kourie; Gil Awada; Ahmad Hussein Awada

doi:10.2217/fon.15.329

Unknown primary tumors: is there a future therapeutic role for immune checkpoint inhibitors?

Future Oncol. 2016 Feb;12(4):429-31. doi: 10.2217/fon.15.329. Epub 2016 Jan 18.

Authors

Hampig Raphael Kourie¹, Gil Awada², Ahmad Hussein Awada¹

Affiliations

¹ Medical Oncology Clinic, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
² Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.

PMID: 26776661
DOI: 10.2217/fon.15.329

No abstract available

Keywords: cancer; checkpoint inhibitors; clinical trial; diagnosis; future; immunotherapies; ipilimumab; nivolumab; pembrolizumab; unknown primary tumor.

Publication types

Editorial

MeSH terms

Antineoplastic Agents / pharmacology*
Antineoplastic Agents / therapeutic use*
Humans
Immunomodulation / drug effects*
Molecular Targeted Therapy*
Neoplasms, Unknown Primary / drug therapy*
Neoplasms, Unknown Primary / immunology*

Substances

Antineoplastic Agents